Navigation Links
Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
Date:3/14/2009

Med Discovery SA, a specialized protein-based therapeutics oncology company, is proud to announce that they have extended their global partnership agreement with Laborium Biopharma, a subsidiary of Validapro BioSciences Inc. to encompass the cell culture process development and clinical manufacturing of all molecules under development at Med Discovery.

(PRWEB) March 14, 2009 -- Med Discovery SA, a specialized protein-based therapeutics oncology company, is proud to announce that they have extended their global partnership agreement with Laborium Biopharma, a subsidiary of Validapro BioSciences Inc. to encompass the cell culture process development and clinical manufacturing of all molecules under development at Med Discovery.

This strategic decision will allow Med Discovery SA to have priority access to Laborium Biopharma's clinical manufacturing capabilities and all related specialized services to ensure compliance of all its development projects to international regulations.

Dr. Deperthes President and CEO at Med Discovery S.A said: "In the upcoming months, Med Discovery will start the manufacturing of new biologics produced in mammalian cells. With this new extended agreement Med Discovery SA will accelerate the development of these innovative products allowing faster entry into pre-clinical and clinical phases. Validapro BioSciences Inc. will bring the operational flexibility and process development expertise to design value-added programs to meet Global cGMP expectations".

Luc Dubois President of Laborium Biopharma added: "In this difficult worldwide financial situation, such partnership agreement opens a new way to do business by sharing respective core competencies to reduce the risk associated with product development. That shall benefit both companies. Validapro BioSciences Inc. will be acting as the process development and clinical manufacturing arm allowing Med Discovery SA to focus at performing the R&D activities for those innovative compounds."

Med Discovery S.A. is a private biopharmaceutical company headquartered in Geneva, Switzerland focusing on treatments for uro-genital cancers. The company is dedicated to the discovery and the development of highly specific protein drugs based on the optimization of natural proteins involved in the regulation of biological pathways. The company is leveraging a strong in-house expertise combined with an international network in clinical urology.

Laborium Biopharma is a private corporation based in the Biotechnology Research Institute of the National Research Council Canada in Montreal, Quebec. This new company is dedicated to the development and optimization of bio-production processes and the cGMP manufacturing of clinical batches of high-potency products.

###

Read the full story at http://www.prweb.com/releases/2009/03/prweb2228834.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
2. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
3. European Centre for Modern Drug Discovery Established in Hamburg
4. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
5. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
8. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
9. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
10. New method of selecting DNA for resequencing accelerates discovery of subtle DNA variations
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
(Date:10/10/2017)... ... October 10, 2017 , ... The ... prestigious awards honoring scientists who have made outstanding contributions to analytical ... during Pittcon 2018, the world’s leading conference and exposition for laboratory science, which ...
Breaking Biology Technology:
(Date:10/4/2017)... Oct. 4, 2017  GCE Solutions, a global clinical research organization ... document anonymization solution on October 4, 2017. Shadow is designed to ... comply with policy 0070 of the European Medicines Agency (EMA) in ... ... ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
Breaking Biology News(10 mins):